Marinus Logo-2in.jpg
Marinus Pharmaceuticals to Be Added to the Russell 2000 and Russell 3000 Index
June 21, 2018 07:30 ET | Marinus Pharmaceuticals, Inc.
Marinus’ addition to the indexes will be effective June 22, 2018, after market close RADNOR, Pa., June 21, 2018 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS) (the “Company”,...
Marinus Logo-2in.jpg
Marinus Pharmaceuticals Initiates Pivotal Phase 3 Trial in Children with CDKL5 Deficiency Disorder
June 19, 2018 07:30 ET | Marinus Pharmaceuticals, Inc.
Marigold Study targets rare form of pediatric epilepsy with no approved therapies RADNOR, Pa., June 19, 2018 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS) (“Marinus” or...
Marinus Logo-2in.jpg
Marinus Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(C)(4)
June 15, 2018 16:05 ET | Marinus Pharmaceuticals, Inc.
RADNOR, Pa., June 15, 2018 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS) (the “Company”, “Marinus”), a biopharmaceutical company dedicated to the development of innovative...
Marinus Logo-2in.jpg
Marinus Pharmaceuticals to Present at Upcoming Investor Conferences
May 30, 2018 07:30 ET | Marinus Pharmaceuticals, Inc.
RADNOR, Pa., May 30, 2018 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS) (the “Company”), a biopharmaceutical company dedicated to the development of innovative therapeutics to...
Marinus Logo-2in.jpg
Marinus Pharmaceuticals to Present at the UBS Global Healthcare Conference
May 14, 2018 07:30 ET | Marinus Pharmaceuticals, Inc.
RADNOR, Pa., May 14, 2018 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and...
Marinus Logo-2in.jpg
Marinus Pharmaceuticals Provides Business Update and First Quarter 2018 Financial Results
May 02, 2018 07:30 ET | Marinus Pharmaceuticals, Inc.
RADNOR, Pa., May 02, 2018 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS) (“Marinus” or “Company”), a biopharmaceutical company dedicated to the development of innovative...
Marinus Logo-2in.jpg
Marinus Pharmaceuticals to Present at the Barclays Global Healthcare Conference
March 08, 2018 07:30 ET | Marinus Pharmaceuticals, Inc.
RADNOR, Pa., March 08, 2018 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and...
Marinus Logo-2in.jpg
Marinus Pharmaceuticals Provides Business Update and 2017 Financial Results
March 06, 2018 07:30 ET | Marinus Pharmaceuticals, Inc.
RADNOR, Pa., March 06, 2018 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and...
Marinus Logo-2in.jpg
Marinus Pharmaceuticals to Attend Upcoming Investor Conferences
February 07, 2018 07:30 ET | Marinus Pharmaceuticals, Inc.
RADNOR, Pa., Feb. 07, 2018 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS) (the “Company”), a biopharmaceutical company dedicated to the development of innovative therapeutics to...
Marinus Logo-2in.jpg
Marinus Pharmaceuticals Added to NASDAQ Biotechnology Index
December 13, 2017 07:30 ET | Marinus Pharmaceuticals, Inc.
RADNOR, Pa., Dec. 13, 2017 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS) (the “Company”), a biopharmaceutical company dedicated to the development of innovative therapeutics to...